11/14
10:14 am
pcrx
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee [Yahoo! Finance]
Low
Report
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee [Yahoo! Finance]
11/14
10:05 am
pcrx
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
Low
Report
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
11/12
10:45 am
pcrx
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Barclays PLC from $25.00 to $17.00. They now have an "equal weight" rating on the stock.
Low
Report
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Barclays PLC from $25.00 to $17.00. They now have an "equal weight" rating on the stock.
11/12
08:00 am
pcrx
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
Medium
Report
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
11/8
08:46 am
pcrx
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
Low
Report
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
11/7
12:32 pm
pcrx
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target raised by analysts at Royal Bank of Canada from $15.00 to $16.00. They now have a "sector perform" rating on the stock.
Low
Report
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target raised by analysts at Royal Bank of Canada from $15.00 to $16.00. They now have a "sector perform" rating on the stock.
11/7
11:47 am
pcrx
Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth [Yahoo! Finance]
Low
Report
Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth [Yahoo! Finance]
11/7
02:31 am
pcrx
Pacira BioSciences Inc (PCRX) Q3 2024 Earnings Call Highlights: Strong Financial Position ... [Yahoo! Finance]
Medium
Report
Pacira BioSciences Inc (PCRX) Q3 2024 Earnings Call Highlights: Strong Financial Position ... [Yahoo! Finance]
11/6
04:00 pm
pcrx
Pacira BioSciences Reports Third Quarter 2024 Financial Results
Low
Report
Pacira BioSciences Reports Third Quarter 2024 Financial Results
11/4
08:00 am
pcrx
Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings
High
Report
Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings
10/30
08:00 am
pcrx
Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024
Low
Report
Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024
10/21
10:40 am
pcrx
Are Options Traders Betting on a Big Move in Pacira BioSciences (PCRX) Stock? [Yahoo! Finance]
Low
Report
Are Options Traders Betting on a Big Move in Pacira BioSciences (PCRX) Stock? [Yahoo! Finance]
10/21
08:00 am
pcrx
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
Low
Report
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
10/7
08:00 am
pcrx
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Medium
Report
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
10/5
08:29 am
pcrx
The three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earnings [Yahoo! Finance]
Medium
Report
The three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earnings [Yahoo! Finance]
10/4
11:58 am
pcrx
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target raised by analysts at Royal Bank of Canada from $14.00 to $15.00. They now have a "sector perform" rating on the stock.
Low
Report
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target raised by analysts at Royal Bank of Canada from $14.00 to $15.00. They now have a "sector perform" rating on the stock.
10/3
08:00 am
pcrx
Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025
Low
Report
Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025
9/26
08:00 am
pcrx
Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
Low
Report
Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
9/25
08:15 am
pcrx
DOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders
Low
Report
DOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders
9/24
12:02 pm
pcrx
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target raised by analysts at Jefferies Financial Group Inc. from $15.00 to $18.00. They now have a "buy" rating on the stock.
Medium
Report
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target raised by analysts at Jefferies Financial Group Inc. from $15.00 to $18.00. They now have a "buy" rating on the stock.
9/9
04:00 pm
pcrx
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Low
Report
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
9/9
11:59 am
pcrx
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]
Low
Report
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]
8/29
12:52 pm
pcrx
Pacira (PCRX) Down 27.9% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
Low
Report
Pacira (PCRX) Down 27.9% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]